A Randomized, Double-blind, 2-Way Crossover Bioequivalence and Adhesion Study of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components at the End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Adult Women
Latest Information Update: 13 Feb 2025
At a glance
- Drugs Ethinylestradiol/norelgestromin (Primary) ; Norelgestromin
- Indications Pregnancy
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
Most Recent Events
- 15 Nov 2021 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 06 Feb 2020 Status changed from recruiting to completed.
- 19 Sep 2019 Planned End Date changed from 4 Feb 2020 to 10 Feb 2020.